125 related articles for article (PubMed ID: 11918672)
1. ICRF-193, a catalytic inhibitor of DNA topoisomerase II, inhibits re-entry into the cell division cycle from quiescent state in mammalian cells.
Hossain MS; Akimitsu N; Takaki T; Hirai H; Sekimizu K
Genes Cells; 2002 Mar; 7(3):285-94. PubMed ID: 11918672
[TBL] [Abstract][Full Text] [Related]
2. DNA topoisomerase II is required for the G0-to-S phase transition in Drosophila Schneider cells, but not in yeast.
Hossain MS; Kurokawa K; Akimitsu N; Sekimizu K
Genes Cells; 2004 Oct; 9(10):905-17. PubMed ID: 15461662
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of DNA topoisomerase II by ICRF-193 induces polyploidization by uncoupling chromosome dynamics from other cell cycle events.
Ishida R; Sato M; Narita T; Utsumi KR; Nishimoto T; Morita T; Nagata H; Andoh T
J Cell Biol; 1994 Sep; 126(6):1341-51. PubMed ID: 8089169
[TBL] [Abstract][Full Text] [Related]
4. Ku antigen is required to relieve G2 arrest caused by inhibition of DNA topoisomerase II activity by the bisdioxopiperazine ICRF-193.
Muñoz P; Baus F; Piette J
Oncogene; 2001 Apr; 20(16):1990-9. PubMed ID: 11360183
[TBL] [Abstract][Full Text] [Related]
5. A novel mechanism of cell killing by anti-topoisomerase II bisdioxopiperazines.
Jensen LH; Nitiss KC; Rose A; Dong J; Zhou J; Hu T; Osheroff N; Jensen PB; Sehested M; Nitiss JL
J Biol Chem; 2000 Jan; 275(3):2137-46. PubMed ID: 10636919
[TBL] [Abstract][Full Text] [Related]
6. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
[TBL] [Abstract][Full Text] [Related]
7. ICRF-193, a catalytic inhibitor of DNA topoisomerase II, delays the cell cycle progression from metaphase, but not from anaphase to the G1 phase in mammalian cells.
Iwai M; Hara A; Andoh T; Ishida R
FEBS Lett; 1997 Apr; 406(3):267-70. PubMed ID: 9136899
[TBL] [Abstract][Full Text] [Related]
8. Selection of human leukemic CEM cells for resistance to the DNA topoisomerase II catalytic inhibitor ICRF-187 results in increased levels of topoisomerase IIalpha and altered G(2)/M checkpoint and apoptotic responses.
Morgan SE; Cadena RS; Raimondi SC; Beck WT
Mol Pharmacol; 2000 Feb; 57(2):296-307. PubMed ID: 10648639
[TBL] [Abstract][Full Text] [Related]
9. Cytogenetic evidence that DNA topoisomerase II is not involved in radiation induced chromsome-type aberrations.
Mosesso P; Pepe G; Ottavianelli A; Schinoppi A; Cinelli S
Mutat Res Genet Toxicol Environ Mutagen; 2015 Nov; 793():14-8. PubMed ID: 26520368
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the biological and biochemical activities of F 11782 and the bisdioxopiperazines, ICRF-187 and ICRF-193, two types of topoisomerase II catalytic inhibitors with distinctive mechanisms of action.
van Hille B; Etiévant C; Barret JM; Kruczynski A; Hill BT
Anticancer Drugs; 2000 Nov; 11(10):829-41. PubMed ID: 11142691
[TBL] [Abstract][Full Text] [Related]
11. Different susceptibilities of postmitotic checkpoint-proficient and -deficient Balb / 3T3 cells to ICRF-193, a catalytic inhibitor of DNA topoisomerase II.
Nishida K; Seto M; Ishida R
Jpn J Cancer Res; 2001 Feb; 92(2):193-202. PubMed ID: 11223549
[TBL] [Abstract][Full Text] [Related]
12. DNA Topoisomerase IIα contributes to the early steps of adipogenesis in 3T3-L1 cells.
Jacobsen RG; Mazloumi Gavgani F; Mellgren G; Lewis AE
Cell Signal; 2016 Oct; 28(10):1593-603. PubMed ID: 27404349
[TBL] [Abstract][Full Text] [Related]
13. Influence of cell cycle and oncogene activity upon topoisomerase IIalpha expression and drug toxicity.
Stacey DW; Hitomi M; Chen G
Mol Cell Biol; 2000 Dec; 20(24):9127-37. PubMed ID: 11094065
[TBL] [Abstract][Full Text] [Related]
14. Casein kinase II-dependent phosphorylation of DNA topoisomerase II suppresses the effect of a catalytic topo II inhibitor, ICRF-193, in fission yeast.
Nakazawa N; Arakawa O; Ebe M; Yanagida M
J Biol Chem; 2019 Mar; 294(10):3772-3782. PubMed ID: 30635402
[TBL] [Abstract][Full Text] [Related]
15. Topoisomerase II inhibitor-induced apoptosis in thymocytes and lymphoma cells.
Kizaki H; Onishi Y
Adv Enzyme Regul; 1997; 37():403-23. PubMed ID: 9381984
[TBL] [Abstract][Full Text] [Related]
16. Hypersensitivity of Ku-deficient cells toward the DNA topoisomerase II inhibitor ICRF-193 suggests a novel role for Ku antigen during the G2 and M phases of the cell cycle.
Muñoz P; Zdzienicka MZ; Blanchard JM; Piette J
Mol Cell Biol; 1998 Oct; 18(10):5797-808. PubMed ID: 9742097
[TBL] [Abstract][Full Text] [Related]
17. Induction of apoptosis by depletion of DNA topoisomerase IIalpha in mammalian cells.
Akimitsu N; Kamura K; Toné S; Sakaguchi A; Kikuchi A; Hamamoto H; Sekimizu K
Biochem Biophys Res Commun; 2003 Jul; 307(2):301-7. PubMed ID: 12859955
[TBL] [Abstract][Full Text] [Related]
18. [Flow cytometric analysis of ICRF-193 influence on cell passage through mitosis].
Shatrova A; Aksenov ND; Zenin VV
Tsitologiia; 2002; 44(11):1068-78. PubMed ID: 12561727
[TBL] [Abstract][Full Text] [Related]
19. Probing the interaction of the cytotoxic bisdioxopiperazine ICRF-193 with the closed enzyme clamp of human topoisomerase IIalpha.
Patel S; Jazrawi E; Creighton AM; Austin CA; Fisher LM
Mol Pharmacol; 2000 Sep; 58(3):560-8. PubMed ID: 10953049
[TBL] [Abstract][Full Text] [Related]
20. Topoisomerase II poisoning by ICRF-193.
Huang KC; Gao H; Yamasaki EF; Grabowski DR; Liu S; Shen LL; Chan KK; Ganapathi R; Snapka RM
J Biol Chem; 2001 Nov; 276(48):44488-94. PubMed ID: 11577077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
